Romosozumab and antiresorptive treatment: the importance of treatment sequence
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Romosozumab and antiresorptive treatment: the importance of treatment sequence
Authors
Keywords
-
Journal
OSTEOPOROSIS INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-15
DOI
10.1007/s00198-021-06174-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis
- (2021) Kosuke Ebina et al. JOINT BONE SPINE
- Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study
- (2021) A. Tominaga et al. OSTEOPOROSIS INTERNATIONAL
- Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk ( ARCH) trial
- (2021) Jacques P. Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE
- (2020) Felicia Cosman Endocrine Practice
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE EXECUTIVE SUMMARY
- (2020) Pauline M. Camacho et al. Endocrine Practice
- T ‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
- (2020) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial
- (2020) Anne Sophie Sølling et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
- (2020) Hideomi Kondo et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate
- (2020) Ian R Reid et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Relationship Between Bone Mineral Density T‐score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
- (2019) S Ferrari et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
- (2019) Mary L Bouxsein et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
- (2019) Pascale Chavassieux et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Standard vs Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial
- (2019) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
- (2019) D.L. Kendler et al. OSTEOPOROSIS INTERNATIONAL
- Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
- (2019) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
- (2018) Michael R McClung et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
- (2018) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
- (2018) Henry G Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
- (2018) David W Dempster et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
- (2018) David L Kendler et al. LANCET
- Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials
- (2018) Tiffany Y. Kim et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
- (2017) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
- (2017) Tony M Keaveny et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis
- (2017) Felicia Cosman et al. MAYO CLINIC PROCEEDINGS
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
- (2016) Paul D. Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
- (2016) Harry K Genant et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
- (2014) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Goal-directed treatment of osteoporosis
- (2013) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis
- (2012) T. Lin et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
- (2011) P. Hadji et al. OSTEOPOROSIS INTERNATIONAL
- Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
- (2010) Ego Seeman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
- (2010) Ian R Reid et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
- (2010) Desmond Padhi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial
- (2009) Kenneth G. Saag et al. ARTHRITIS AND RHEUMATISM
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
- (2009) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*
- (2008) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
- (2008) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis
- (2007) Steven Boonen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started